Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205349 | 0.83 | BRPF1 (0.47) | ALDH1A1HPGDCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL19644386 | 0.79 | NR4A2 (0.54) | ALDH1A1HPGDNR4A2LMNARAB9A | |
| SCHEMBL19657777 | 0.78 | — | — | |
| SCHEMBL4301614 | 0.77 | CSNK2A1 (0.56) | ALDH1A1HPGDCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL16205508 | 0.74 | MAPT (0.44) | ALDH1A1HPGDLMNAGAARAB9A | |
| SCHEMBL19657598 | 0.73 | NR4A2 (0.35) | NR4A2 | |
| SCHEMBL22822744 | 0.72 | LMNA (0.30) | LMNA | |
| SCHEMBL19644343 | 0.72 | CSNK2A2 (0.36) | ALDH1A1HPGDCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4300488 | 0.71 | CYP1A2 (0.63) | ALDH1A1HPGD | |
| SCHEMBL20487884 | 0.70 | BRPF1 (0.46) | ALDH1A1HPGDCSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | ALDH1A1 2185/4885HPGD 2280/4885CSNK2A2 116/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885CSNK2A2 119/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885CSNK2A2 119/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885CSNK2A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.